title: Imatinib mesylate treatment in a patient with chemoresistant Ph+ acute myeloid leukemia: possible role of Wilms' tumor gene 1.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Quartarone
authors.forename: Alessandro
authors.initials: A
authors.lastname: Allegra
authors.forename: Andrea
authors.initials: A
authors.lastname: Alonci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Toscano
authors.forename: Giacomo
authors.initials: G
authors.lastname: Bellomo
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Corigliano
authors.forename: Vittorio
authors.initials: V
authors.lastname: Del Fabro
authors.forename: Caterina
authors.initials: C
authors.lastname: Musolino
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D005260:Female; D016162:Genes, Wilms Tumor / Q000502:physiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000209:etiology*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate